WEKO3
アイテム
Ten-year Experiences of Carbon lon Therapy with HIMAC
https://repo.qst.go.jp/records/61946
https://repo.qst.go.jp/records/619465e7411f7-7598-47ff-b98a-62cc3531ece9
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2006-12-06 | |||||
| タイトル | ||||||
| タイトル | Ten-year Experiences of Carbon lon Therapy with HIMAC | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Tsujii, Hirohiko
× Tsujii, Hirohiko× 辻井 博彦 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | In June 1994 the National Institute of Radiological Sciences(NIRS)initiated carbon ion therapy using the Heavy ion Medical Accelerator in Chiba(HIMAC).The HIMAC is the world's first heavy particle accelerator for medical use and aiso serves as a multipurpose,shared facility jointly used for cancer therapy and dasic research. After clinical trials had been carried out for vsrious types of malignat tumoes,the institute was successful in pbtaining approval from the Ministry of Health,Welfaer and Labor for its`Highly Advanced Medical Technology"in October 2003. This means that carbon ion therapy has meanswhile achieved for itself a solid place in general practice after the clinical experiences of a whole ten years. As of February 2005,the number of patients registered is in excessf2,000.Experiences to date indicate that carbon beam therapy is advantageous for: 1 by histology, adenocarcinoma, adenoid cystic carcinoma and sarcoma (malignant melanoma and bone/soft-tTissue sarcoma): 2 by tumor origin,skull base,herd and neck,lung,liver,prostate,bone/soft tissus,and pelvis: 3 by locattion,tumors located in the vicinity of critical organs such as the eye,spinal chord,digestive tract with irregular shape.Tumors that infiltrate or originate in the digestive tract, however,appeared difficult to control with carbon ions alone. he number of patients continues to rise incessantly year after year,due not only to the way in which the irradiation techniques have been established but also as a result of the significant reduction in the number of fractions per patient.There is a rationale to justify the use of shot-course RT due to the superior dose localization and the unique biological property of carbon ions.This has been proved in treatment for early stage NSCLC and hepatoma, where the fraction number has been successfully shortened to 1-4 fractions in 1-7 days.Even in prostate canaer and bone/soft tissus tumor,treatment has been performed using 16 to 20 fractions in 4 to 5 week with acceptable morbidity,roughly half the number of fractions required in the case of otherexternal radiotherapy. This means that the facility can be operated more efficiently,offering treatment for a larger number of patients than is possible with other modalitiea over the same period of time. Currently,the number of irradiation sessions per patient averages 13 fractions over three weeks in carbon ion therapy. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | PTCOG42(Particle Therapy Co-operative Group Meeting) | |||||
| 発表年月日 | ||||||
| 日付 | 2005-06-10 | |||||
| 日付タイプ | Issued | |||||
